These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16645006)

  • 1. Peroxisome proliferator-activated receptor gamma agonists in renal disease.
    Iglesias P; Díez JJ
    Eur J Endocrinol; 2006 May; 154(5):613-21. PubMed ID: 16645006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproteinuric and anti-inflammatory effects of thiazolidinedione.
    Szeto CC; Li PK
    Nephrology (Carlton); 2008 Feb; 13(1):53-7. PubMed ID: 18199104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PPAR receptors and insulin sensitivity: new agonists in development].
    Pégorier JP
    Ann Endocrinol (Paris); 2005 Apr; 66(2 Pt 2):1S10-7. PubMed ID: 15959400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
    Cho N; Momose Y
    Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
    Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP
    Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
    Ruilope L; Hanefeld M; Lincoff AM; Viberti G; Meyer-Reigner S; Mudie N; Wieczorek Kirk D; Malmberg K; Herz M
    BMC Nephrol; 2014 Nov; 15():180. PubMed ID: 25407798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A step ahead of PPARγ full agonists to PPARγ partial agonists: therapeutic perspectives in the management of diabetic insulin resistance.
    Chigurupati S; Dhanaraj SA; Balakumar P
    Eur J Pharmacol; 2015 May; 755():50-7. PubMed ID: 25748601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage.
    Garcia-Vallvé S; Guasch L; Tomas-Hernández S; del Bas JM; Ollendorff V; Arola L; Pujadas G; Mulero M
    J Med Chem; 2015 Jul; 58(14):5381-94. PubMed ID: 25734377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.
    Doshi LS; Brahma MK; Bahirat UA; Dixit AV; Nemmani KV
    Expert Opin Investig Drugs; 2010 Apr; 19(4):489-512. PubMed ID: 20367191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
    Blaschke F; Caglayan E; Hsueh WA
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
    Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
    Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.
    Setti G; Hayward A; Dessapt C; Barone F; Buckingham R; White K; Bilous R; Hiroshi K; Gruden G; Viberti G; Gnudi L
    Am J Nephrol; 2010; 32(5):393-402. PubMed ID: 20814199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.
    Higgins LS; Depaoli AM
    Am J Clin Nutr; 2010 Jan; 91(1):267S-272S. PubMed ID: 19906796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential.
    Yang J; Zhang D; Li J; Zhang X; Fan F; Guan Y
    Clin Sci (Lond); 2009 Jan; 116(1):17-26. PubMed ID: 19037881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes.
    Gelman L; Feige JN; Desvergne B
    Biochim Biophys Acta; 2007 Aug; 1771(8):1094-107. PubMed ID: 17459763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPAR dual agonists: are they opening Pandora's Box?
    Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
    Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.